Full Press Release Details
Oncolytics Biotech Inc. Appoints Dr. Matt Coffey
to the Role of President and CEO
CALGARY, Jan. 19, 2017 /CNW/ - Oncolytics Biotech
Inc. ("Oncolytics" or the "Company") (TSX: ONC) (OTCQX: ONCYF) today announced that Matt Coffey PhD, MBA, has
been appointed to the role of President and Chief Executive Officer, effective immediately. Dr. Coffey had been serving as the
Company's Interim President and Chief Executive Officer since early November 2016.
"Dr. Coffey has transitioned seamlessly into his new
role and, together with the expanded senior management team, has rapidly crafted plans to advance a range of clinical and operational
initiatives," said Wayne Pisano, Chairman of Oncolytics' Board of Directors. "After careful consideration and review,
taking into account his extensive knowledge of REOLYSIN , tenure with the Company, and efforts to date, the Board
has determined that Dr. Coffey is ideally positioned to lead Oncolytics' ongoing efforts to move a first in class immuno-oncology
viral agent through late-stage clinical testing."
A co-founder of the Company, Dr. Coffey completed his doctorate
degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his
research have been published in various respected scientific journals, including Science, Human Gene Therapy, and
The EMBO Journal. Dr. Coffey has held progressively senior roles with Oncolytics including, Chief Operating Officer since
December 2008, Chief Scientific Officer, Vice-President of Product Development and Chief Financial Officer.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics'
clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN ,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements
within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking
information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in
this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in
the future, including the impact on Oncolytics and its clinical program of the change in senior management of Oncolytics, and other
such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties,
which could cause the Company's actual results to differ materially from those in the forward-looking statements and forward-looking
information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency of patient enrollment
numbers in separate patient groups, the availability of funds and resources to pursue research and development projects, the efficacy
of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside
a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize
REOLYSIN , uncertainties related to the research and development of pharmaceuticals and uncertainties related to
the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward-looking statements and forward-looking
information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information.
The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by
SOURCE Oncolytics Biotech Inc.
For further information: NATIONAL Equicom, Nick Hurst, 320
Front Street W, Suite 1600, Toronto, Ontario, M5V 3B6, Tel: 416.586.1942, nhurst@national.ca; NATIONAL Equicom, Michael Moore,
San Diego, CA, Tel: 858.886.7813, mmoore@national.ca
CO: Oncolytics Biotech Inc.
CNW 06:30e 19-JAN-17